Table 4.
Clinical features of PD cases by use of paraquat or rotenone or mechanistic group.
| Paraquat
|
Any oxidative stressor
|
Rotenone
|
Any complex I inhibitor
|
|||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | Exposed (n = 23) | Not exposed (n = 74) | Exposed (n = 35) | Not exposed (n = 53) | Exposed (n = 19) | Not exposed (n = 82) | Exposed (n = 36) | Not exposed (n = 59) |
| Age at PD diagnosis [years (mean ± SD)] | 59 ± 8 | 62 ± 9 | 59 ± 8 | 64 ± 9* | 65 ± 11 | 61 ± 8 | 61 ± 11 | 62 ± 8 |
| PD duration [years (mean ± SD)] | 8.6 ± 6 | 8.4 ± 6 | 8.2 ± 6 | 7.6 ± 5 | 7.7 ± 7 | 8.7 ± 5 | 8.2 ± 6 | 8.5 ± 5 |
| Clinical features [n with feature/n with data available (%)] | ||||||||
| Resting tremor | 21/22 (95) | 66/73 (90) | 31/34 (91) | 49/53 (92) | 17/18 (94) | 75/81 (93) | 32/35 (91) | 54/58 (93) |
| Bradykinesia | 22/23 (96) | 70/74 (95) | 33/35 (94) | 50/53 (94) | 17/19 (89) | 79/82 (96) | 34/36 (94) | 56/59 (95) |
| Rigidity | 23/23 (100) | 72/73 (99) | 33/34 (97) | 50/53 (94) | 18/19 (95) | 80/80 (100) | 34/35 (97) | 58/58 (100) |
| Postural reflex impairment | 10/21 (48) | 43/62 (69) | 18/31 (58) | 29/43 (67) | 7/15 (47) | 48/69 (70) | 16/28 (57) | 37/52 (71) |
| Asymmetric onset | 23/23 (100) | 69/71 (97) | 35/35 (100) | 49/51 (96) | 18/18 (100) | 77/79 (97) | 35/35 (100) | 54/56 (96) |
| Response to dopaminergic therapy (if prescribed) | 21/21 (100) | 63/65 (97) | 30/30 (100) | 46/48 (96) | 14/15 (93) | 73/74 (99) | 30/31 (97) | 53/54 (98) |
*
Difference between exposed versus not exposed p = 0.02.